CLONICEL (Clonidine HCl sustained release)

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Attention Deficit Hyperactivity Disorder

Conditions

Attention Deficit Hyperactivity Disorder

Trial Timeline

Jan 1, 2008 โ†’ Jun 1, 2010

About CLONICEL (Clonidine HCl sustained release)

CLONICEL (Clonidine HCl sustained release) is a phase 3 stage product being developed by Shionogi for Attention Deficit Hyperactivity Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00723190. Target conditions include Attention Deficit Hyperactivity Disorder.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00723190Phase 3Completed

Competing Products

20 competing products in Attention Deficit Hyperactivity Disorder

See all competitors
ProductCompanyStageHype Score
atomoxetineEli LillyApproved
85
Atomoxetine + PlaceboEli LillyPhase 2/3
65
AtomoxetineEli LillyApproved
85
Atomoxetine HydrochlorideEli LillyApproved
85
AtomoxetineEli LillyPhase 3
77
AtomoxetineEli LillyApproved
85
Atomoxetine hydrochloride + PlaceboEli LillyApproved
85
Donepezil hydrochloride + PlaceboEisaiPhase 3
77
LY2216684 + Methylphenidate + Placebo (tablet) + Placebo (capsule)Eli LillyPhase 2/3
65
Atomoxetine + PlaceboEli LillyApproved
85
AtomoxetineEli LillyApproved
85
AtomoxetineEli LillyPre-clinical
23
Atomoxetine HydrochlorideEli LillyApproved
85
Atomoxetine hydrochlorideEli LillyPhase 3
77
Atomoxetine Hydrochloride + PlaceboEli LillyApproved
85
atomoxetineEli LillyPhase 3
77
atomoxetine 0.5 mg/kg/day + placebo + atomoxetine 1.2 mg/kg/day + atomoxetine 1.2-1.4 mg/kg/dayEli LillyPhase 3
77
Atomoxetine HydrochlorideEli LillyApproved
85
Atomoxetine HydrochlorideEli LillyPhase 3
77
Atomoxetine Hydrochloride + Methylphenidate Hydrochloride + PlaceboEli LillyPhase 3
77